Piper Jaffray Companies began coverage on shares of Stemline Therapeutics (NASDAQ:STML) in a research report report published on Sunday. The brokerage issued an overweight rating and a $12.26 price target on the biopharmaceutical company’s stock.
Several other research firms also recently weighed in on STML. BidaskClub upgraded Stemline Therapeutics from a hold rating to a buy rating in a research note on Wednesday, September 19th. ValuEngine upgraded Stemline Therapeutics from a hold rating to a buy rating in a research note on Tuesday, August 14th. Zacks Investment Research upgraded Stemline Therapeutics from a sell rating to a hold rating in a research note on Thursday, August 16th. HC Wainwright set a $38.00 price target on Stemline Therapeutics and gave the company a buy rating in a research note on Friday, August 10th. Finally, Wedbush reiterated an outperform rating and set a $22.00 price target on shares of Stemline Therapeutics in a research note on Monday, November 12th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company’s stock. Stemline Therapeutics has an average rating of Buy and a consensus price target of $26.32.
Shares of NASDAQ:STML opened at $10.99 on Friday. Stemline Therapeutics has a 1 year low of $10.00 and a 1 year high of $20.55. The stock has a market cap of $349.49 million, a P/E ratio of -3.74 and a beta of 0.58.
In other Stemline Therapeutics news, COO Kenneth Hoberman sold 26,296 shares of the business’s stock in a transaction dated Monday, November 26th. The stock was sold at an average price of $11.85, for a total transaction of $311,607.60. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 14.80% of the stock is currently owned by insiders.
Institutional investors have recently bought and sold shares of the business. BlueMountain Capital Management LLC purchased a new stake in Stemline Therapeutics during the 2nd quarter valued at about $137,000. State Board of Administration of Florida Retirement System purchased a new stake in shares of Stemline Therapeutics in the second quarter worth about $166,000. MetLife Investment Advisors LLC boosted its stake in shares of Stemline Therapeutics by 54.6% in the third quarter. MetLife Investment Advisors LLC now owns 18,474 shares of the biopharmaceutical company’s stock worth $307,000 after buying an additional 6,527 shares during the last quarter. Bank of America Corp DE boosted its stake in shares of Stemline Therapeutics by 97.8% in the second quarter. Bank of America Corp DE now owns 20,548 shares of the biopharmaceutical company’s stock worth $329,000 after buying an additional 10,159 shares during the last quarter. Finally, Algert Global LLC purchased a new stake in shares of Stemline Therapeutics in the second quarter worth about $344,000. Institutional investors and hedge funds own 62.39% of the company’s stock.
About Stemline Therapeutics
Stemline Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary oncology therapeutics in the United States and internationally. The company develops SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R), which has completed Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm; is in Phase I/II clinical trials for patients with myeloproliferative neoplasms, chronic myelomonocytic leukemia, myelofibrosis, and acute myeloid leukemia; and is in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma.
Featured Article: NASDAQ Stock Market Explained
Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.